It will be interesting to see whether PYC are also targeting some of the mid tier pharma i.e: the many specialty pharma companies that are doing quite well pursuing niche indications and that have a greater tolerance for risk. Companies such as Shire, UCB Pharma, Cephalon, Genzyme, Forest Labs, Lundbeck, etc... As with the big pharmas, they still tend to rely on smaller companies (like PYC) for innovation but like I've mentioned on a previous thread, they're doing deals earlier and pricing them more aggressively.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.39 |
Change
0.030(2.21%) |
Mkt cap ! $810.7M | |||
| Open | High | Low | Value | Volume |
| $1.39 | $1.39 | $1.33 | $103.4K | 75.90K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2600 | $1.37 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.39 | 14999 | 1 |
View Market Depth
| Last trade - 16.10pm 21/07/2025 (20 minute delay) ? |
| PYC (ASX) Chart |